Chief Financial Officer

Nuvalent presents preliminary data for neladalkib from ALKOVE-1 Phase 1/2 trial

Nuvalent Presents Preliminary Data for Neladalkib in Advanced ALK-positive Solid Tumors Beyond NSCLC at ESMO 2025

Nuvalent resumed with a Buy at Stifel

Nuvalent Insider Sold Shares Worth $2,540,290, According to a Recent SEC Filing

Director, Medical Affairs Strategy

Nuvalent is an early-stage company focused on creating selective medicines for cancer patients. The Director of Medical Affairs Strategy will be responsible for developing and executing Medical Affairs strategies, collaborating with various teams to ensure alignment and successful implementation of medical initiatives.

Sign up with Google

Sign in with Google